In a note to investors, Needham & Co. agreed with Medtronic’s pitch that Cornerstone’s Sentire platform can ultimately complement Hugo, especially in a global robotic surgery market that the medtech giant says has plenty of room to grow, estimating it as only 5% penetrated.
Earlier this month, Medtronic said it would invest $700 million in the Hong Kong–based Cornerstone in return for the rights to distribute Sentire across certain international markets. The soft-tissue robot carries regulatory clearances across 50 countries — compared to Hugo’s 35 — including China and Singapore, as well as a CE Mark in Europe that spans gynecologic, urologic and general surgeries.
Sentire’s design more closely competes with industry leader Intuitive, they wrote, especially its lower-end da Vinci X system with four robotic arms anchored by a central column and an immersive surgeon console. The more-modular Hugo, meanwhile, places arms on separate wheeled carts with the goal of offering more flexibility to hospitals and fitting into more operating rooms.
“While the Hugo design has advantages, we believe that there is a group of customers accustomed to da Vinci that may prefer to stick with its design philosophy,” Needham analysts wrote. “While we understand investor cynicism, we believe that the design and cost differences between the two systems legitimately positions them in different market segments which supports management’s claims.”
The analysts added that Medtronic’s portfolio approach is a similar tack to Intuitive, which offers the da Vinci 5 and da Vinci Xi platforms at higher-end tiers compared to the da Vinci X. While prices have not been disclosed, they expect Sentire to come in below Hugo given its manufacturing base in Shenzhen, China.
Medtronic has not declared which specific countries will be covered in its partnership. The company has said that at this point it does not plan on selling Sentire in the U.S., where Hugo has been on the market for about eight months, following its FDA nod in December 2025. However, Needham analysts said that could change based on Sentire’s international adoption, as well as future crossovers between the two systems.
Medtronic is ‘doubling down’
At the Wells Fargo Healthcare Conference this month, Medtronic CEO Geoff Martha said the company is “doubling down in robotics,” with Hugo focused on developed markets and Sentire offering more choices outside the U.S., especially in Asia.
“We’re both at important moments — like in the U.S. for Hugo, we’ve got new indications coming. We’ll cross 50,000 cases by the end of the year, and 250 unit installations around the world. And we’ve got new instruments coming,” Martha said. “So that’s where we’re focused. And Sentire is just starting their launch. They’re going to be starting their launch and they’re more focused outside the U.S.”
The sentiment was echoed by Chief Financial Officer Thierry Pieton earlier this week, at Morgan Stanley’s healthcare conference.
“What we’ve discovered is customers in this vastly growing field want choices. Some of them want modular form factors. Some of them want a boom design. Some of them want an open visualization, others want immersive,” said Pieton. “So it’s become clear to us that you need to offer choice and access.”
“We have the capability to help them with the distribution. They have the capability to offer this choice to our customers,” he added. “This is about us going on offense in this high-growth sector and just being on top of it. So we made a large investment.”
